These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25926498)

  • 1. Effects of Frozen Storage on Detection of Intermediate Vancomycin Susceptibility and Heteroresistance in Methicillin-Resistant Staphylococcus aureus Blood Isolates.
    Riederer K; Iyer S; Shemes S; Dejaeghere V; Sharma M; Szpunar S; Khatib R
    J Clin Microbiol; 2015 Jul; 53(7):2392. PubMed ID: 25926498
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus.
    Ludwig F; Edwards B; Lawes T; Gould IM
    J Clin Microbiol; 2012 Oct; 50(10):3383-7. PubMed ID: 22855515
    [No Abstract]   [Full Text] [Related]  

  • 3. Vancomycin susceptibility of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia isolates from two UK hospitals over a decade.
    Karas JA; Enoch DA; Fish D; Foweraker JE
    Int J Antimicrob Agents; 2010 Aug; 36(2):189-90. PubMed ID: 20451354
    [No Abstract]   [Full Text] [Related]  

  • 4. Decreasing prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus among blood isolates in Korean hospitals.
    Kang YR; Chung DR; Baek JY; Kim SH; Cho SY; Ha YE; Kang CI; Peck KR; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):464-466. PubMed ID: 27720209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best alternative to vancomycin for serious methicillin-resistant Staphylococcus aureus infections: let's just say it.
    Bush LM
    Clin Infect Dis; 2011 Nov; 53(9):965-6. PubMed ID: 21880584
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.
    van Hal SJ; Wehrhahn MC; Barbagiannakos T; Mercer J; Chen D; Paterson DL; Gosbell IB
    J Clin Microbiol; 2011 Apr; 49(4):1489-94. PubMed ID: 21270232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycopeptide and daptomycin susceptibility and vancomycin heteroresistance of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates from a Greek university hospital.
    Panagea T; Galani I; Souli M; Karantani I; Giamarellou H; Petrikkos G
    Int J Antimicrob Agents; 2011 Nov; 38(5):451-2. PubMed ID: 21840688
    [No Abstract]   [Full Text] [Related]  

  • 9. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used.
    Prakash V; Lewis JS; Jorgensen JH
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4528. PubMed ID: 18838599
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia.
    Khosrovaneh A; Riederer K; Saeed S; Tabriz MS; Shah AR; Hanna MM; Sharma M; Johnson LB; Fakih MG; Khatib R
    Clin Infect Dis; 2004 May; 38(9):1328-30. PubMed ID: 15127350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doubtful model utility in predicting high vancomycin minimum inhibitory concentration methicillin-resistant Staphylococcus aureus bloodstream infection episodes.
    van Hal SJ; Jones M; Paterson DL; Gosbell IB
    Clin Infect Dis; 2011 Dec; 53(11):1166-7; author's reply 1167-8. PubMed ID: 22021926
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.
    Kosowska-Shick K; Ednie LM; McGhee P; Smith K; Todd CD; Wehler A; Appelbaum PC
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4510-3. PubMed ID: 18838583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin susceptibility of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia isolates in an Italian hospital.
    Bassetti M; Mesini A; Molinari MP; Viscoli C
    Int J Antimicrob Agents; 2011 Nov; 38(5):453-4. PubMed ID: 21872450
    [No Abstract]   [Full Text] [Related]  

  • 14. Low prevalence of vancomycin heteroresistance among meticillin-resistant Staphylococcus aureus causing bacteraemia in Hong Kong.
    Ho PL; Siu JT; Law PY; Lai EL; Tse CW; Lee R; Kao RY; Cheng VC; Que TL
    Int J Antimicrob Agents; 2012 Dec; 40(6):564-6. PubMed ID: 23040009
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) using the KeyPath MRSA/MSSA blood culture test and the BacT/ALERT system in a pediatric population.
    Sullivan KV; Turner NN; Roundtree SS; McGowan KL
    Arch Pathol Lab Med; 2013 Aug; 137(8):1103-5. PubMed ID: 23899068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
    Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT
    Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus.
    Deresinski S
    J Infect Dis; 2009 Mar; 199(5):605-9. PubMed ID: 19199551
    [No Abstract]   [Full Text] [Related]  

  • 19. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC.
    Chong YP; Park SJ; Kim HS; Kim ES; Kim MN; Kim SH; Lee SO; Choi SH; Jeong JY; Woo JH; Kim YS
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):264-6. PubMed ID: 22621914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.